ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Lazarus Discusses Companion Diagnostics

Tadd Lazarus, MD
Published: Thursday, Sep 18, 2014

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Diagnostics provide the foundation of care, Lazarus says, and companion diagnostics are no exception. Ten years ago, 5-10% of drugs in the pipeline had a corresponding biomarker – today, up to 45% of drugs do.

Companion diagnostics allow clinicians to select the group of patients that will most likely respond to that drug. New drugs, Lazarus says, often have a better safety profile compared with older drugs but must be used selectively due to cost and other factors.

Tadd Lazarus, MD, Chief Medical Officer, QIAGEN, provides an overview of companion diagnostics.

Diagnostics provide the foundation of care, Lazarus says, and companion diagnostics are no exception. Ten years ago, 5-10% of drugs in the pipeline had a corresponding biomarker – today, up to 45% of drugs do.

Companion diagnostics allow clinicians to select the group of patients that will most likely respond to that drug. New drugs, Lazarus says, often have a better safety profile compared with older drugs but must be used selectively due to cost and other factors.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x